Skip to main content
Erschienen in: Journal of Interventional Cardiac Electrophysiology 3/2021

11.05.2020 | Atrial Fibrillation

Rationale and study design for ablation of paroxysmal atrial fibrillation guided by ablation index: a multi-center, prospective randomized trial (PAF-AI trial)

verfasst von: Ruhong Jiang, Minglong Chen, Jie Fan, Fu Yi, Anli Tang, Xingpeng Liu, Wenqing Zhu, Shaowen Liu, Xiaobo Huang, Weizhu Ju, Xi Zhang, Jie Li, Jiangui He, Liang Shi, Genqing Zhou, Yuegang Wang, Chenyang Jiang

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Pulmonary vein isolation (PVI) has become the cornerstone of atrial fibrillation (AF) ablation, but long-term success rates remains suboptimal, due in large part to late PV reconnection and insufficient ostial substrate modification.

Objective

To evaluate whether ablation index (AI)–guided PVI with electrical isolation and quantified ostial substrate modification improves clinical outcomes when compared with contact force (CF)–guided ablation in patients with paroxysmal atrial fibrillation (PAF).

Methods

The PAF-AI trial (ChiCTR1900022041) is a prospective, multi-center, randomized controlled clinical trial enrolling patients with PAF with an indication for catheter ablation. Patients are randomized into a 2:1 fashion to two treatment arms: AI-guided PVI (n = 151) and CF-guided PVI (n = 75). In the AI-guided PVI group, real-time automated display of radiofrequency applications (Visitag™) is used with AI ≥ 500 recommended at the anterior/superior/inferior walls and 350–400 at the posterior wall. In CF-guided PVI group, the value and direction of CF are displayed, with the lesion dots manually annotated. The primary endpoint is the freedom from AF recurrence at 12 months following ablation, without antiarrhythmic drug. The primary pre-specified secondary endpoints include intraprocedural efficiency and peri-procedural complications.

Conclusions

PAF-AI trial compares the effectiveness and safety of two different strategies of PVI in patients with PAF, AI-guided PVI versus more established CF-guided PVI. This prospective, multi-center, randomized controlled trial, with comparative data evaluating procedural and long-term follow-up results, aims to evaluate the impact of AI-guided strategy on AF ablation compared with the current standard of care RF ablation approach.
Literatur
3.
Zurück zum Zitat Reddy VY, Dukkipati SR, Neuzil P, Natale A, Albenque JP, Kautzner J, et al. Randomized, controlled trial of the safety and effectiveness of a contact force-sensing irrigated catheter for ablation of paroxysmal atrial fibrillation: results of the TactiCath contact force ablation catheter study for atrial fibrillation (TOCCASTAR) study. Circulation. 2015;132(10):907–15. https://doi.org/10.1161/CIRCULATIONAHA.114.014092.CrossRefPubMed Reddy VY, Dukkipati SR, Neuzil P, Natale A, Albenque JP, Kautzner J, et al. Randomized, controlled trial of the safety and effectiveness of a contact force-sensing irrigated catheter for ablation of paroxysmal atrial fibrillation: results of the TactiCath contact force ablation catheter study for atrial fibrillation (TOCCASTAR) study. Circulation. 2015;132(10):907–15. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​114.​014092.CrossRefPubMed
12.
17.
Zurück zum Zitat Dhillon G, Ahsan S, Honarbakhsh S, Lim W, Baca M, Graham A, et al. A multicentered evaluation of ablation at higher power guided by ablation index: establishing ablation targets for pulmonary vein isolation. J Cardiovasc Electrophysiol. 2018;30:357–65. https://doi.org/10.1111/jce.13813.CrossRef Dhillon G, Ahsan S, Honarbakhsh S, Lim W, Baca M, Graham A, et al. A multicentered evaluation of ablation at higher power guided by ablation index: establishing ablation targets for pulmonary vein isolation. J Cardiovasc Electrophysiol. 2018;30:357–65. https://​doi.​org/​10.​1111/​jce.​13813.CrossRef
19.
Zurück zum Zitat Nakagawa H, Ikeda A, Govari A, Papaioannou T, Constantine G, Bar-Tal M, et al. Prospective study using a new formula incorporating contact force, radiofrequency power and application time (Force-Power-Time Index) for quantifying lesion formation to guide long continuous atrial lesions in the beating canine heart. Am Heart Assoc; 2013. Nakagawa H, Ikeda A, Govari A, Papaioannou T, Constantine G, Bar-Tal M, et al. Prospective study using a new formula incorporating contact force, radiofrequency power and application time (Force-Power-Time Index) for quantifying lesion formation to guide long continuous atrial lesions in the beating canine heart. Am Heart Assoc; 2013.
22.
Zurück zum Zitat Chen S, Schmidt B, Bordignon S, Urbanek L, Tohoku S, Bologna F, et al. Ablation index-guided 50 W ablation for pulmonary vein isolation in patients with atrial fibrillation: procedural data, lesion analysis, and initial results from the FAFA AI high power study. J Cardiovasc Electrophysiol. 2019;30(12):2724–31. https://doi.org/10.1111/jce.14219.CrossRefPubMed Chen S, Schmidt B, Bordignon S, Urbanek L, Tohoku S, Bologna F, et al. Ablation index-guided 50 W ablation for pulmonary vein isolation in patients with atrial fibrillation: procedural data, lesion analysis, and initial results from the FAFA AI high power study. J Cardiovasc Electrophysiol. 2019;30(12):2724–31. https://​doi.​org/​10.​1111/​jce.​14219.CrossRefPubMed
Metadaten
Titel
Rationale and study design for ablation of paroxysmal atrial fibrillation guided by ablation index: a multi-center, prospective randomized trial (PAF-AI trial)
verfasst von
Ruhong Jiang
Minglong Chen
Jie Fan
Fu Yi
Anli Tang
Xingpeng Liu
Wenqing Zhu
Shaowen Liu
Xiaobo Huang
Weizhu Ju
Xi Zhang
Jie Li
Jiangui He
Liang Shi
Genqing Zhou
Yuegang Wang
Chenyang Jiang
Publikationsdatum
11.05.2020
Verlag
Springer US
Erschienen in
Journal of Interventional Cardiac Electrophysiology / Ausgabe 3/2021
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-020-00763-5

Weitere Artikel der Ausgabe 3/2021

Journal of Interventional Cardiac Electrophysiology 3/2021 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.